[Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia].
The efficacy of clarithromycin retarded release dosage form in the treatment of patients with community-acquired pneumonia was estimated in a open prospective comparative study. The drug was administered in a dose of 500 mg once a day (29 patients) and in a dose of 500 mg twice a day (28 patients). The clinical efficacy in the compared regimens amounted to 90.6 and 93.3% of the patients respectively and the bacteriological efficacy was 93.3 and 84.6% respectively. The adverse reactions were observed in 15.6 and 30.0% of the cases respectively.